Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 5
2007 7
2008 7
2009 5
2010 7
2011 15
2012 8
2013 12
2014 13
2015 7
2016 5
2017 7
2018 3
2019 2
2020 6
2021 6
2022 6
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. da Silva EM, et al. Cochrane Database Syst Rev. 2016 Feb 5;2(2):CD008185. doi: 10.1002/14651858.CD008185.pub4. Cochrane Database Syst Rev. 2016. PMID: 26845288 Free PMC article. Review.
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of participants at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels. ...
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of p …
Idursulfase in Hunter syndrome treatment.
Zareba G. Zareba G. Drugs Today (Barc). 2007 Nov;43(11):759-67. doi: 10.1358/dot.2007.43.11.1157619. Drugs Today (Barc). 2007. PMID: 18174963 Free article. Review.
Results of the randomized, double-blind, placebo-controlled phase II/III clinical trial of idursulfase demonstrated that weekly infusions of idursulfase increase walking distance and improve pulmonary function as well as reduce organ size and urinary glycosaminoglyc …
Results of the randomized, double-blind, placebo-controlled phase II/III clinical trial of idursulfase demonstrated that weekly infus …
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. da Silva EM, et al. Cochrane Database Syst Rev. 2014 Jan 8;(1):CD008185. doi: 10.1002/14651858.CD008185.pub3. Cochrane Database Syst Rev. 2014. PMID: 24399699 Updated. Review.
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of patients at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels. ...
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of p …
Idursulfase: I2S, iduronato-2-sulfatase.
[No authors listed] [No authors listed] Drugs R D. 2006;7(4):254-8. doi: 10.2165/00126839-200607040-00005. Drugs R D. 2006. PMID: 16784250 Review. No abstract available.
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. da Silva EM, et al. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008185. doi: 10.1002/14651858.CD008185.pub2. Cochrane Database Syst Rev. 2011. PMID: 22071845 Updated. Review.
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of patients at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels. ...
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of p …
Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
Muenzer J, Burton BK, Harmatz P, Gutiérrez-Solana LG, Ruiz-Garcia M, Jones SA, Guffon N, Inbar-Feigenberg M, Bratkovic D, Hale M, Wu Y, Yee KS, Whiteman DAH, Alexanderian D; SHP609-302 study group. Muenzer J, et al. Mol Genet Metab. 2022 Sep-Oct;137(1-2):92-103. doi: 10.1016/j.ymgme.2022.07.016. Epub 2022 Aug 2. Mol Genet Metab. 2022. PMID: 35961250 Free article. Clinical Trial.
A formulation of idursulfase for intrathecal administration (idursulfase-IT) is under investigation for the treatment of neuronopathic MPS II. ...Participants were also enrolled in this extension from a linked non-randomized sub-study of children younger than 3 year …
A formulation of idursulfase for intrathecal administration (idursulfase-IT) is under investigation for the treatment of neuro …
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA, Kimura A. Whiteman DA, et al. Drug Des Devel Ther. 2017 Aug 23;11:2467-2480. doi: 10.2147/DDDT.S139601. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28860717 Free PMC article. Review.
Preclinical studies utilizing the intravenous route of administration provided valuable insights that informed the design of the subsequent clinical studies. The pivotal Phase II/III clinical trial of intravenous idursulfase (Elaprase(); Shire, Lexington, MA, USA) demonstr …
Preclinical studies utilizing the intravenous route of administration provided valuable insights that informed the design of the subsequent …
Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II.
Muenzer J, Vijayaraghavan S, Stein M, Kearney S, Wu Y, Alexanderian D. Muenzer J, et al. Genet Med. 2022 Jul;24(7):1437-1448. doi: 10.1016/j.gim.2022.04.002. Epub 2022 May 20. Genet Med. 2022. PMID: 35588317 Free article. Clinical Trial.
PURPOSE: Intrathecal (IT) idursulfase-IT for the treatment of cognitive impairment is being investigated in pediatric patients with neuronopathic mucopolysaccharidosis II (MPS II) in addition to intravenous idursulfase. ...RESULTS: In total, 15 participants received …
PURPOSE: Intrathecal (IT) idursulfase-IT for the treatment of cognitive impairment is being investigated in pediatric patients with n …
A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, Solanki GA, Mascelli MA, Pan L, Wang N, Sciarappa K, Barbier AJ. Muenzer J, et al. Genet Med. 2016 Jan;18(1):73-81. doi: 10.1038/gim.2015.36. Epub 2015 Apr 2. Genet Med. 2016. PMID: 25834948 Free article. Clinical Trial.
Intravenous (i.v.) enzyme replacement therapy does not affect cognitive impairment because recombinant iduronate-2-sulfatase (idursulfase) does not penetrate the blood-brain barrier at therapeutic concentrations. We examined the safety of idursulfase formulat …
Intravenous (i.v.) enzyme replacement therapy does not affect cognitive impairment because recombinant iduronate-2-sulfatase (idursulfase …
Idursulfase for the treatment of mucopolysaccharidosis II.
Clarke LA. Clarke LA. Expert Opin Pharmacother. 2008 Feb;9(2):311-7. doi: 10.1517/14656566.9.2.311. Expert Opin Pharmacother. 2008. PMID: 18201153 Review.
The latest addition to this group is mucopolysaccharidosis II or Hunter syndrome. Purified human recombinant idursulfase has been shown to alter disease manifestations in individuals with Hunter syndrome. The recent approval in the US, Europe, Canada and Japan of idursu …
The latest addition to this group is mucopolysaccharidosis II or Hunter syndrome. Purified human recombinant idursulfase has been sho …
109 results